Vaibhavi Shah

Inventia Healthcare Ltd. engages in the development and manufacture of pharmaceutical formulations. It caters anti-diabetic, gastrointestinal, CVC, CNS and musculoskeletal therapeutic areas. The company was founded by Janak Shah and Maya Shah in 1985 and is headquartered in Mumbai, India.

GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan.

Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.